Back

AstraZeneca PLC

Ticker: AZN ISIN: GB0009895292
Add to portfolio Portfolio analysis in 2min
Stock Large-cap Dividend payer
Market cap
GBX 177.73B
P/E
23.15
Forward P/E
15.08
Profit margin
17.02%
Revenue growth QoQ
6.40%
Div. yield
2.76%
Beta
0.21
GBX 11,650.00 -1.90%
Price as of 2026-09-09 · LSE

Performance by timeframe

Rolling returns
1 Month -1.64%
6 Months -18.36%
1 Year -0.55%
5 Years +9.81% p.a.+59.65%
10 Years +12.26% p.a.+217.57%
Since inception +9.13% p.a.+787.61%
Calendar year returns
YTD -14.07%
2025 +34.59%
2024 +0.92%
2023 -3.53%
2022 +32.32%
2021 +21.78%

Key stats

Market cap
177.73B
P/E
23.15
Dividend yield
2.76%
Beta
0.21
52-week range
9,826.66 - 15,467.70
50-day MA
13,026.64
200-day MA
13,830.71
Section 1

Business overview

Company profile data from fundamentals.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Sector Healthcare
Industry Drug Manufacturers - General
Country United Kingdom
Exchange LSE
Section 2

Financial quality

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE 21.97%
ROA 8.02%
Profit margin 17.02%
Operating margin 23.46%
PEG ratio 1.33
Revenue/share TTM 39.59
Revenue TTM 61.37B
EBITDA 19.90B
Gross profit TTM 50.13B
Beta 0.21

Valuation

Trailing P/E 23.15
Forward P/E 15.08
P/B 4.77
P/S 2.90
EV/EBITDA 13.12
EV/Revenue 4.35

ESG Scores

Total ESG 28.5
Environment 0.2
Social 15.4
Governance 8.9
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 10.26
Quarterly earnings growth 2.50%
Revenue TTM 61.37B
Reported quarters 80
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Dividend yield 2.76%
Forward annual div. yield 1.78%
Dividend per share 3.2300
Payout ratio 26.80%
Ex-dividend date 2025-08-07
Next dividend date 2026-09-08
Last split date 0000-00-00
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Ownership & short interest

Shares outstanding 1.55B
Shares float 1.54B
Institutional ownership 55.59%
Insider ownership 2.70%
Short ratio 0.00
Short % of float 4.26%

Details

Instrument metadata and source update timestamps.

Symbol AZN
Name AstraZeneca PLC
Asset type STOCK
Exchange LSE
Currency GBX
ISIN GB0009895292
Country UK
Code + exchange AZN.LSE
Last price date 2026-08-17
Fundamentals updated 2026-08-17

The information provided on this platform is for informational purposes only and should not be considered as financial or investment advice. Insightfolio does not provide investment advice, personalized recommendations, or guidance regarding the purchase, holding, or sale of financial assets. The tools and content are intended for educational purposes only and are not tailored to individual circumstances, financial needs, or objectives.

Insightfolio assumes no liability for the accuracy, completeness, or reliability of the information presented. Users are solely responsible for verifying the information and making independent decisions based on their own research and careful consideration. Use of the platform should not replace consultation with qualified financial professionals.

Investments involve risks. Users should be aware that the value of investments may fluctuate and that past performance is not an indicator of future results. Investment decisions should be based on personal financial goals, risk tolerance, and independent evaluation of relevant information.

Insightfolio does not endorse or guarantee the suitability of any particular financial product, security, or strategy. Any projections, forecasts, or hypothetical scenarios presented on the platform are for illustrative purposes only and are not guarantees of future outcomes.

By accessing the services, information, or content offered by Insightfolio, users acknowledge and agree to these terms of the disclaimer. If you do not agree to these terms, please do not use our platform.

Instrument logos provided by Elbstream.